Han Hoon

Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU.

AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA.

Hucord Co., Ltd. is a biotechnology company engaged in human cell-based therapy. It develops stem cell technology along with the cord blood, specializing in Multi-Lineage Progenitor Cells (MLPCs) research, treatment of disease and banking of cells. The group works in the following divisions: cord blood banking, stem cell banking, stem cell research and development, stem cell therapy management and the immunogenetics laboratory. It also performs the Human leukocyte antigen typing method which determines the compatibility of tissues between patient and the donor. The company was founded on January 24, 1979 and is headquartered in Yongin-si, South Korea.